Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

506
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
506
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

716
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

470
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
470
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

584
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.

BJU international·2026
Same author

First-line Therapy for Metastatic Renal Cell Carcinoma: An Updated Network Meta-analysis using Final Follow-up Data.

European urology focus·2026
Same author

From Genes to Proteins: The Indispensable Role of Proteogenomics in Advancing Clear Cell Renal Cell Carcinoma Research.

International journal of molecular sciences·2026
Same author

Reply to Kristoffer Mazanti Cold, Lars Konge, and Sarah Hjartbro Bube's Letter to the Editor re. Roessler N, Miszczyk M, Miyajima K, et al. Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review. Eur Urol Focus. In press. http://dx.doi.org/10.1016/j.euf.2025.12.007.

European urology focus·2026
Same author

Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma.

Cancer medicine·2026
Same author

Ultrasound measurement of the optic nerve and its sheath using the CLOSED protocol: comparison with MRI in a porcine in-vivo model.

BMC veterinary research·2026

Related Experiment Video

Updated: Mar 16, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Mechanical circulatory support in heart failure.

Bożena Szyguła-Jurkiewicz1, Wioletta Szczurek2, Kamil Suliga2

  • 13 Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.

Kardiochirurgia I Torakochirurgia Polska = Polish Journal of Cardio-Thoracic Surgery
|August 13, 2016
PubMed
Summary

Ventricular assist devices (VADs) offer improved survival and quality of life for end-stage heart failure patients when donor hearts are scarce. While beneficial, VADs carry risks like bleeding and infection.

Keywords:
heart failuremechanical circulatory support

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.7K

Related Experiment Videos

Last Updated: Mar 16, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.7K

Area of Science:

  • Cardiology and Cardiovascular Surgery
  • Biomedical Engineering
  • Medical Device Technology

Background:

  • Rising end-stage heart failure (EHF) patient numbers exceed donor heart availability.
  • Ventricular assist devices (VADs) are increasingly crucial for managing EHF.
  • Mechanical circulatory support (MCS) offers alternatives for transplant-ineligible patients.

Purpose of the Study:

  • To provide an updated overview of Mechanical Circulatory Support (MCS) in contemporary medicine.
  • To highlight the role of VADs in bridging patients for heart transplantation or as destination therapy.
  • To discuss the benefits and risks associated with VAD implantation.

Main Methods:

  • Literature review of current knowledge on MCS and VADs.
  • Analysis of VAD applications: bridge to decision, recovery, candidacy, and destination therapy.
  • Synthesis of data on the advantages and potential complications of VADs.

Main Results:

  • MCS, including VADs, significantly improves organ perfusion and function.
  • VADs enhance patient quality of life and survival rates.
  • Potential complications include bleeding, infection, arrhythmias, and thromboembolic events.

Conclusions:

  • VADs are a vital therapeutic option for EHF patients, addressing donor organ shortages.
  • Careful patient selection and management are essential to mitigate VAD-related risks.
  • MCS represents a significant advancement in managing advanced heart failure.